ANTIBODIES

OVERVIEW OF THE MJFF ANTIBODY REPOSITORY

MJFF partners with Abcam to license and distribute antibodies generated by academic labs.

Abcam distributes the antibodies to non-profit and for-profit researchers under terms agreed upon by Abcam and the depositing investigator/institution.

There is no cost for transferring hybridoma lines or recombinant antibody sequences to Abcam.

REPOSITORY WORKFLOW

MJFF and PI who owns the antibody agree to transfer rights to the antibody to Abcam for distribution.

Abcam reaches out to the PI and institution to obtain information on the antibody, negotiate licensing, and coordinate shipment (if needed).

If needed, PI ships vials of the hybridoma line to Abcam. The line and antibody undergo QC. The option to keep the antibody private until publication is available.

Abcam builds a product page to host your line. The page includes information on the species reactivity, verified applications, and publications.

The antibody undergoes QC and is listed as available for researchers to access.

HOW TO ADD YOUR ANTIBODY TO THE REPOSITORY

For ASAP-funded tools: Please complete the ASAP Tool Submission form. A link to the form is here and in the “MJFF Sponsored Tools Program” section of the Discover ASAP page on the Hub.

For non-ASAP-funded tools: Please email tools@michaeljfox.org. Provide the name of the lab that developed the antibody, a brief description of the antibody and comment on how this tool will accelerate research.

PROGRAM BENEFITS

Depositing your antibody in the MJFF repository provides the benefits of:

- **Reducing costs** associated with maintaining the hybridoma line and purifying antibody
- **Reducing time wasted** on fielding requests, processing MTAs, and shipping aliquots
- **Protecting against loss** or contamination by ensuring the antibody-expressing cell line is banked in a secondary location
- **Increased visibility** of your antibody as researchers find it on the MJFF Tools Catalog and repository website
- **Crowd sourcing additional characterization** of the antibody through broad community access
- **Timely availability** of the antibody post-publication when the antibody is shared in advance and kept in a private collection until publication.

These benefits are all gained while retaining ownership of the antibody and the right to license directly to collaborators.